

Brian Roberts-Stanton

PO Box 1166, Alachua, Florida 32616 •• 443.994.0747 •• BRobStan@Gmail.com

Education

PhD	Biology/Molecular Genetics	University of Maryland	1988
BS	Biology	Rensselaer Polytechnic Institute	1982

Professional Experience

Vice-Chair , Patent Agents Committee, AIPLA, Washington, DC.	10/2014-Present
Principal/Lead Strategist , Stanton Consulting Services, LLC, Alachua, FL.	06/2012-Present
Director , Consulting and Analysis Branch, The REDANDA Group, Inc., New Market, MD.	02/2007 – Present
Director , Division of Policy, Office of Technology Transfer, National Institutes of Health (NIH), Bethesda, MD.	09/2003 - 10/2007
Quality Assurance Specialist , Technology Center 1600, Biotechnology and Pharmaceutical Chemistry, U.S. Patent and Trademark Office (USPTO), Arlington, VA.	10/2002 – 09/2003
Biotech/Pharm Business Practice Specialist , Technology Center 1600, USPTO, Arlington, VA.	10/1999 – 10/2002
Supervisory Patent Examiner , USPTO, Arlington, VA.	10/1998 – 09/1999
Examiner/Primary Patent Examiner , USPTO, Crystal City, VA.	08/1992 – 09/1998
Post-Doctoral Fellow , Frederick Cancer Research and Development Center (FCRDC), National Cancer Institute (NCI), Frederick, MD.	10/1988 – 08/1992
Pre-Doctoral Fellow , FCRDC, NCI, Frederick, MD.	08/1985 – 10/1998
Teaching Assistant , Developmental Biology, University of Maryland, Baltimore, MD.	08/1982 – 08/1985
Laboratory Worker , Wadsworths Center for Laboratories and Research, New York State Department of Health, Albany, NY.	09/1980 – 06/1982
Research Assistant , Rensselaer Polytechnic Institute, Department of Chemistry, Troy, NY.	01/1979 – 03/1980
Guest Worker , CIBA-Geigy Pharmaceutical Corporation, Ardsley, NY.	01/1978 – 06/1978

Recent Activities

Expert , Canada, Networks of Centers for Excellence, Business led (BL) Expert panel review, Ottawa, Ontario, Canada	October 2012
Member , AIPLA, Special Committee on Legislation, Washington, DC	October 2012-Present
Director , Biolyst, LLC (Realief Neuropathy Centers), Minneapolis, MN	April 2012-Present
Lecturer , University of Florida, Gainesville, FL	January 2012-Present
Advisor , NIH Genetic Testing Working Group, Washington, DC	July 2011
Consultant , Bio-fuels production, Gainesville, FL	January 2012-present

Research Experience

<i>Embryonic Stem Cells, Homologous Recombination, Embryology, and Oncogenes</i> , Post-Doctoral Fellow; Frederick Cancer Research and Development Center (FCRDC), National Cancer Institute (NCI), Frederick, MD.	1988-1992
<i>TrkB is the High Affinity Nerve Growth Factor Receptor</i> , Pre-Doctoral Fellow, FCRDC, NCI, Frederick, MD.	1985-1988
<i>Alternative Oncogene splicing in the c-fms gene</i> , Pre-Doctoral Fellow, FCRDC, NCI, Frederick, MD.	1984-1988
<i>Skeletal Muscle Retro-Differentiation by SV40</i> , University of Maryland, Baltimore County, Catonsville, MD.	1982-1984
<i>Studies on a-fetoprotein, neural tube defects, and prenatal diagnostics</i> , NY State Department of Health, Albany, NY.	1981-1982
<i>Oxidase induction in Neurospora crassa</i> , Rensselaer Polytechnic Institute, Department of Chemistry, Troy, NY.	1978-1981
<i>Carbohydrate Metabolism in Rat Brain Caudate Nucleus</i> , Ciba-Geigy Corporation, Ardsley, NY.	1978-1978

Teaching Experience

Adjunct Professor , Foundation for the Advancement of Education in Science (FAES), Bethesda, MD.	2000-2011
Assistant Professor , U.S. Office of Personnel Management, Eastern Management Development Center (EMDC), Shepherdstown, WV.	1996-2006
Visiting Professor , Georgetown University Law School, Washington, DC.	1997-2001
Adjunct Professor , University of Maryland, College Park, MD.	1990-1992
Teaching Assistant , University of Maryland, Baltimore, MD.	1982-1984
Teaching Assistant , Elementary Education, The Hackley School, Tarrytown, NY.	1978-1978

Affiliations/Memberships

American Intellectual Property Law Association (AIPLA)
 Association for the Advancement of Science (AAAS)
 New York Academy of Science
 Patent and Trademark Office Society (PTOS)
 Licensing Executive Society (LES)
 Washington Academy of Science
 New York Academy of Science
 American Association of Independent Investors
 SBA/SCORE

Certifications/Authorities

Primary Patent Examiner, 2006

Supervisory Patent Examiner, 2008
Federal Contract Officer certification, 2003
Patent Agent (Reg. No. 56,253), 2004

Awards/Honors

Nominated for Department of Commerce **Gold Medal** for Meritorious Service (2000)
Department of Commerce **Bronze Medal** for Meritorious Service (2002)
Department of Commerce **Bronze Medal** for Sustained Superior Service (2001)
Department of Commerce **Bronze Medal** for Meritorious Service (1999)
On-the-Spot Awards for **Superior Service**, USPTO (2000, 2001)
U.S. Patent and Trademark Office, **Superior Achievement Awards** (1994-1998, Annual)
Ant Award, **Superior Service**, Patent and Trademark Office Society (1995)
Distinguished Graduate, U.S. Patent and Trademark Office (1994)
Ciba-Geigy Award in Science (1978)
New York State Regent Scholarship (1978)
Special Achievement/Recognition in Mathematics and Computer Science (1978)
Rensselaer Medal for Science (1977)

Selected Technical Publications

Moens, C.B., **Stanton, B.R.**, Parada, L.F., and Rossant, J. 1993. "Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the *N-myc* locus." **Development** 119(2): 485-499.

Stanton, B.R., Perkins, A.S., Tessarollo, L., Sassoon, D.A., and Parada, L.F. 1992. "Loss of *fN-myc* function results in embryonic lethality and failure of epithelial components of the embryo to develop." **Genes and Development** 6(12): 71-83.

Stanton, B.R. and Parada, L.F. 1992. "The *N-myc* protooncogene: Developmental expression and *in vivo* site directed mutagenesis." **Brain Pathology** 2: 71-83.

Soppet, D., Escandaon, E., Maragos, J., Middlemas, D.S., Reid, S.W., Blair, J., Burton, L.E., **Stanton, B.R.**, Kaplan, D.R., Hunter, T., Nikolics, K., and Parada, L.F. 1991. "The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the *trkB* tyrosine kinase receptor." **Cell** 65: 895-903.

Stanton, B.R., Reid, S.W., and Parada, L.F. 1990. "Analysis of murine *N-myc* function in nervous system development by *in situ* hybridization and homologous recombination." **Journal of Cellular Biochemistry**, Supplement 14 Part F: 56.

Stanton, B.R. Reid, S.W., and Parada, L.F. 1990. "Germ line transmission of an inactive *N-myc* allele generated by homologous recombination in mouse embryonic stem cells." **Molecular and Cellular Biology** 10: 6755-6758.

Mizejewski, G.J., **Stanton, B.R.**, and Jacobson, H.I. 1989. "AFP Modification of biologic response n estrogen-sensitive tissues: Use of *in vivo* and *in vitro* models." In: **Biological Activities of α -fetoprotein, Volume II** (Mizejeski, G.J. and Jacobson, H.I., eds.) (1989): 59-73.

Psychoyos, S., **Stanton, B.R.**, and Jacobson, H.I. 1989. "The influence of glucose, other monosaccharides, and ascorbic acid on tyrosine hydroxylase activity of rat striatal synaptosomes." **Life Sciences** 25 No.13 (1989): 1119-1125.

Selected Invited Technical Reports and Presentation

"Disruption of *N-myc* Function in the Mouse by Homologous Recombination Results in Midgestation Lethality." **Mouse Molecular Genetics Meeting**. Heidelberg, Germany, August 1991.

“Disruption of N-*myc* Function in the Mouse by Homologous Recombination Results in Midgestation Lethality.” **Seventh Annual Meeting on Oncogenes**. Hood College, Frederick, MD, June 1991.

“Growth Factor Induced Tyrosine Phosphorylation of *trkB*.” **Seventh Annual Meeting on Oncogenes**. Hood College, Frederick, MD, June 1991.

“The Expression of *c-ros* Protooncogene Receptor is Tightly Regulated During Mouse Development.” **Seventh Annual Meeting on Oncogenes**. Hood College, Frederick, MD, June 1991.

“Expression and Mutational Analysis of Protooncogenes During Neural Development.” **Transgenic Mice in Developmental Biology and Toxicology**. National Institute of Environmental and Health Sciences, Research Triangle Park, NC, April 1991.

“Analysis of Murine N-*myc* Function in Nervous System Development by *in situ* Hybridization and Homologous Recombination.” **UCLA Symposium on Molecular Embryology**. South Padre Island, TX, April 1990.

“Analysis of Murine N-*myc* Function in Nervous System Development by *in situ* Hybridization and Homologous Recombination.” **UCLA Symposium**. Tamarron, CO, January 1990.

“Alpha-fetoprotein Regulates Cell Responses to Estrogen and Mediates Tissue Uptake of Estradiol,” **The Endocrine Society**. Baltimore, MD, August 1985.

Domestic (U.S.A.) Policy Documents and White Papers (Author/Coauthor)

“Gene Patents, Licensing Practices and Their Impact on Patient Access to Genetic Tests,” Report of the Secretary’s Advisory Committee on Genetics, Health, and Society, (SACGHS) Washington DC (2010).

Dissent to the “SACGHS Report on Gene Patent and Access to Genetic Testing,” Washington, DC (2009).

“Cutting-Edge Practices and Considerations in Technology Transfer,” National Academy of Science, Washington, DC (2004).

“Utility Patent Examination Guidelines,” 66 FR 1092 (January 5, 2001) US Patent and Trademark Office, Washington, DC (2001).

“Guidelines for Examination of Patent Applications Under the 35 U.S.C. 112, ¶1, “Written Description” Requirement,” 66 FR 1099 (January 5, 2001) U.S. Patent and Trademark Office, Washington, DC (2001).

“Patent Pools: A Solution To The Problem Of Access In Biotechnology Patents?” U.S. Patent and Trademark Office, Washington, DC (2000).

“Genes: The Stuff of Life? The Whole is Greater than the Sum of the Parts! ” U.S. Patent and Trademark Office, Washington, DC (2000).

“Who Owns Life? The USPTO Perspective on Patenting Life”, US Patent and Trademark Office, Washington, DC (1999).

“Revised Interim Utility Guidelines Training Materials,” U.S. Patent and Trademark Office, Washington, DC (1999).

“Synopsis of Application of Written Description Guidelines,” U.S. Patent and Trademark Office, Washington, DC (1999).

International Studies/White Papers (Author/Coauthor)

Trilateral Project B3b: Mutual understanding in search and examination; Report on Comparative study on biotechnology patent practices Theme: Comparative study on ‘reach-through claims.’ USPTO/EPO/JPO, San Francisco, California (November 2001).

Trilateral Project WM4: COMPARATIVE studies in new technologies (biotechnology, business methods, etc.) Report on comparative study on protein 3-dimensional (3-D) structure related claims. USPTO/EPO/JPO, Vienna, Austria (November 2002).

Trilateral Project WM4: Comparative studies in new technologies (biotechnology, business methods, etc.) Report on comparative study on examination practice relating to single nucleotide polymorphisms (SNPs) and haplotypes. USPTO/EPO/JPO, Tokyo, Japan (June 2003).

Trilateral Project B3b: Mutual understanding in search and examination; Comparative study on biotechnology patent practices; Theme: Nucleic acid molecule-related inventions whose functions are inferred based on homology search. USPTO/EPO/JPO, Washington, DC (November 2001).

Selected Intellectual Property (IP) Publications

Mark L. Rohrbaugh and Brian R. Stanton, 2009. “Technology Transfer at the National Institutes of Health,” in **Technology Transfer in Biotechnology: A Global Perspective**, Ganguli, Prabuddha; Pickril, Ben; Khanna, Rita, eds. Wiley-VCH, 35-58.

Kunin, S.G., Nagumo, M., **Stanton, B.**, Therkorn, L.S., and Walsh, S., 2002. “Reach-Through Claims in the Age of Biotechnology.” **American University Law Review** 51(4): 609-638.

Clark, J., Piccolo, J., **Stanton, B.**, Tyson, K., 2000. “Patent Pools: A Solution to the Problem of Access In Biotechnology Patents?” White paper issue by the USPTO, (<http://www.uspto.gov/web/offices/pac/dapp/opla/patentpool.pdf>)

Feisee, L., **Stanton, B.**, and Parr, M., March 2000. “Our Customers, Our Partners: Biotech and Pharmaceutical Partnerships Improve Quality,” **PTO Today** 1(3):1.

Feisee, L. and **Stanton, B.**, March 2000. “Are Biotechnology Patents Important?” **PTO Pulse**.

Brian R. Stanton, (August 26, 2009). “Deputy for Patent Exam Policy: The Devil is in the Details,” **IPWatchdog**, IPWatchdog.com, <http://www.ipwatchdog.com/2009/08/26/deputy-for-patent-examination-policy/id=5272/>.

Brian R. Stanton, (December 26, 2014), “Can Diagnostics Companies Afford to Provide Ebola Testing?” **IPWatchdog**, IPWatchdog.com, <http://www.ipwatchdog.com/2014/12/26/can-diagnostics-companies-afford-to-provide-ebola-testing/id=52779/>.

Selected Invited Intellectual Property Addresses

“Myriad Genetics and Gene Patenting,” Progress Park, **University of Florida**, Gainesville, FL, 2013.

“Update: Trade, IP, and Global Security.” **University of Florida**, Gainesville, FL, 2012.

“America Invents Act,” **GAIN**, Gainesville, FL, 2012

“Restriction Practice,” **AIPLA Patent Prosecution Bootcamp**, Washington, DC, 2012.

“Gene Patenting,” **National Press Club**, Washington, DC, 2009.

“Intellectual Property,” **OPM**, EMDC, Shepherdstown, VA, 2004.

“Patent Office Perspectives: Examination Practice,” **NIH**, FAES, Bethesda, MD, 2003, 2004.

“Reach Through Claim Scope,” **Boston Patent Law Association**, Boston, MA, 2004.

“Patentability of Reach Through Claims,” **Biotechnology Customer Partnership**, USPTO, Alexandria, VA, 2003.

“Homology Claim Language,” **Biopharmaceutical Customer Partnership**, USPTO, Alexandria, VA, 2002.

“Gene Patents and How They Are Used in Diagnostics,” **US Government Accountability Office (GAO)**, Washington, DC, 2002.

“Legislation, Case Law, and Patent Practice in Biotechnology,” **Licensing Executive Society (LES)**, Washington, DC, 2002.

“Gene Patenting,” **Intellectual Property Owners (IPO) Association**, Washington, DC, 2002.

“Utility, Written Description, and Gene Patenting,” **Japan Productivity Center for Socio-Economic Development (JP-PCSD)**, Washington, DC, 2001.

“Strategies for Success in Claiming Biotechnology Inventions,” **Strategic Resource Institute (SRI)**, Irvine, CA, 2001.

“Current Practices in Biotechnology,” **National Institutes of Health (NIH)**, Bethesda, MD, 2001.

“Hot Topics and Examination Practices in Biotechnology,” **Independent Inventors Conference**, Washington, DC, 2001.

“Chemical Restriction Practice: Thoughts and Perspectives,” **American Intellectual Property Law Association (AIPLA)**, New Orleans, LA, 2001.

“Utility and Written Description in Patent Law,” **Philadelphia Intellectual Property Law Association**, Philadelphia, PA, 2000.

“Utility and Gene Patenting,” **Federation of American Societies for Experimental Biology (FASEB)**, Washington, DC, 2000.

“Utility, Written Description, and Gene Patenting,” **Science Writers Association**, Washington, DC, 2000.

“Discovery Genetics,” **Washington PLA**, Seattle, WA, 2000.

“Patentability Issues in Biotechnology and Pharmaceuticals,” **Boston Intellectual Property Law Association**, Boston, MA, 2000.

“Patentability Considerations for Embryonic Stem Cells, Gene Therapy, and Transgenic Animals,” **Biotechnology Industry Organization (BIO)**, Washington, DC, 2000.

“Careers in Patents,” **American Association of Cell Biologists**, Washington, DC, 1999.

Cases In Which I Have Testified In Court Or By Deposition

IN RE: METHOD OF PROCESSING ETHANOLBYPRODUCTS AND RELATED SUBSYSTEMS ('858) PATENT LITIGATION, Master Case No. 1:10-ml-02181-LJM-DML, (United States District Court For The Southern District Of Indiana Indianapolis Division)